CSI Market
Sign In | Register

Rapt Therapeutics Inc (RAPT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RAPT Annual Cash Flow →
A period-by-period view of cash flow from Rapt Therapeutics Inc to Sep 30 2024 helps clarify how Sep 30 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-52.39
Depreciation & amortization0.69
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation14.21
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Noncash Interest Income Loss Net-
Investment Income Amortization Of Premium-
Investment Income Net Amortization Of Discount And Premium-
Non Cash Operating Lease Expense1.65
Increase Decrease In Deferred Rent Current And Noncurrent-
Increase Decrease In Operating Lease Liability-2.09
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.24
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.18
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-37.27
Discontinued operations0.00
Net Cash flow from Operating Activities-76.14
Investing Activities
Capital Expenditures-0.08
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities130.62
Payments to Acquire Marketable Securities-186.40
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-55.86
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.20
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-169.74
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations169.74
Offering Costs Included In Accounts Payable And Accrued Expenses-
Proceeds From Issuances Of Common Stock In At The Market Offerings Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.20
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-76.23
Total Cash Flow-131.81
4 historic quarters locked

Sign in to unlock the full Rapt Therapeutics Inc cash flow history.

Sign In Create Free Account

About Rapt Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-25-268141

Figures are derived from filed reports and may be restated. Historical data is subject to revision.